A phase 3 trial to compare efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab versus sunitinib alone in first-line treatment of patients with metastatic renal cell carcinoma.

被引：5
|
作者：
Motzer, Robert J.
Grunwald, Viktor
Hutson, Thomas E.
Porta, Camillo
Powles, Thomas
Eto, Masatoshi
Dutcus, Corina E.
Baig, Mahadi Ali
Dutta, Lea
Li, Di
Choueiri, Toni K.
机构：
[1] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[2] Hannover Med Sch, Niedersachsen, Germany
[3] Baylor Univ, Med Ctr, Dallas, TX USA
[4] IRCCS San Matteo Univ Hosp Fdn, Pavia, Italy
[5] Barts Hlth NHS Trust St Bartholomews Hosp, London, England
[6] Kyushu Univ, Fukuoka, Japan
[7] Eisai Inc, Woodcliff Lake, NJ USA
[8] Harvard Med Sch, Brigham & Womens Hosp, Dana Farber Canc Inst, Boston, MA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 06期
关键词：
D O I：
10.1200/JCO.2018.36.6_suppl.TPS706
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS706
引用
收藏
页数：1
相关论文
共 50 条
  • [1] A Phase III Trial to Compare Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab vs Sunitinib Alone in First-Line Treatment of Patients With Metastatic Renal Cell Carcinoma (RCC)
    Motzer, Robert J.
    Grunwald, Viktor
    Hutson, Thomas E.
    Porta, Camillo
    Powles, Thomas
    Eto, Masatoshi
    Dutcus, Corina
    Baig, Mahadi A.
    Dutta, Lea
    Li, Di
    Young, Louise
    Choueiri, Toni K.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2017, 13 : 169 - 169
  • [2] A phase III trial to compare efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab vs sunitinib alone in first-line treatment of patients (Pts) with metastatic renal cell carcinoma (RCC)
    Motzer, Robert J.
    Grunwald, Viktor
    Hutson, Thomas E.
    Porta, Camillo
    Fowles, Thomas
    Eto, Masatoshi
    Dutcus, Corina E.
    Baig, Mahadi Ali
    Dutta, Lea
    Li, Di
    Choueiri, Toni K.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [3] Comparative efficacy of sunitinib versus sorafenib as the first-line treatment for patients with metastatic renal cell carcinoma.
    Park, Seongjoon
    Lee, Jae-Lyun
    Park, Inkeun
    Park, Kwonoh
    Ahn, Yongchel
    Ahn, Jin-Hee
    Lee, Dae Ho
    Song, Cheryn
    Hong, Jun Hyuk
    Kim, Choung-Soo
    Ahn, Hanjong
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [4] Phase II Randomized Trial Comparing Sequential First-Line Everolimus and Second-Line Sunitinib Versus First-Line Sunitinib and Second-Line Everolimus in Patients With Metastatic Renal Cell Carcinoma
    Motzer, Robert J.
    Barrios, Carlos H.
    Kim, Tae Min
    Falcon, Silvia
    Cosgriff, Thomas
    Harker, W. Graydon
    Srimuninnimit, Vichien
    Pittman, Ken
    Sabbatini, Roberto
    Rha, Sun Young
    Flaig, Thomas W.
    Page, Ray
    Bavbek, Sevil
    Beck, J. Thaddeus
    Patel, Poulam
    Cheung, Foon-yiu
    Yadav, Sunil
    Schiff, Edward M.
    Wang, Xufang
    Niolat, Julie
    Sellami, Dalila
    Anak, Oezlem
    Knox, Jennifer J.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (25) : 2766 - +
  • [5] Efficacy and safety of first-line sunitinib in Chinese patients with metastatic renal cell carcinoma
    Qin, Shu-Kui
    Jin, Jie
    Guo, Jun
    Wang, Jin-Wan
    Zhou, Fang-Dian
    Huang, Yi-Ran
    Ren, Xiu-Bao
    Ye, Ding-Wei
    Pan, Sharon
    Sajben, Peter
    Wang, Qiao
    FUTURE ONCOLOGY, 2018, 14 (18) : 1835 - 1845
  • [6] EFFICACY AND SAFETY OF SUNITINIB AS FIRST-LINE TREATMENT IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA: SYSTEMATIC REVIEW
    Huerfano, C.
    NinoNino, C. P.
    Davila, F.
    Reyes, J. M.
    Diaz, J. A.
    VALUE IN HEALTH, 2016, 19 (03) : A169 - A169
  • [7] COMPARATIVE EFFICACY OF SUNITINIB VERSUS SORAFENIB AS THE FIRST-LINE TREATMENT FOR PATIENTS WITH METASTATIC RENAL CELL CARCINOMA
    Park, S. J.
    Lee, J.
    Park, I.
    Park, K.
    Ahn, J.
    Lee, D. H.
    Song, C.
    Hong, J. H.
    Kim, C.
    Ahn, H.
    ANNALS OF ONCOLOGY, 2012, 23 : 287 - 288
  • [8] Comparative Efficacy of Sunitinib versus Sorafenib as First-Line Treatment for Patients with Metastatic Renal Cell Carcinoma
    Park, Seong Joon
    Lee, Jae-Lyun
    Park, Inkeun
    Park, Kwonoh
    Ahn, Yongcheol
    Ahn, Jin-Hee
    Lee, Dae-Ho
    Ahn, Shin
    Song, Cheryn
    Hong, Jun Hyuk
    Kim, Choung-Soo
    Ahn, Hanjong
    CHEMOTHERAPY, 2012, 58 (06) : 468 - 474
  • [9] Phase I study of sunitinib in combination with gemcitabine/capecitabine for the first-line treatment of metastatic or unresectable renal cell carcinoma.
    Suarez, C.
    Gallardo, E.
    Rodon Ahnert, J.
    Guix, M.
    Bonfill, T.
    Pons, F.
    Beltran, M.
    Moya, I.
    Galtes, S.
    Albanell, J.
    Carles, J.
    Bellmunt, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [10] Efficacy of pembrolizumab plus lenvatinib as first-line treatment for metastatic renal cell carcinoma with multiple brain metastases
    Matsumoto, Daisuke
    Naiki, Taku
    Naiki-Ito, Aya
    Aoki, Maria
    Kato, Shinji
    Morikawa, Toshiharu
    Shimizu, Nobuhiko
    Gonda, Masakazu
    Umemoto, Yukihiro
    Yasui, Takahiro
    IJU CASE REPORTS, 2025, 8 (01) : 5 - 9
12345